Charged Alpha logo
CHARGED ALPHA
Stock Analysis
ABT Healthcare Latest YouTube: Q2 2026 Published 2026-07-17

Abbott Laboratories

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

ABT Stock: Abbott Beat AND Raised — So Why Is It Still Down 27%? (Bargain or Value Trap?)

Published 2026-07-17

Library coverage

Episodes tracked
4
Episodes linked
4
Latest video
Q2 2026
2026-07-17
Podcast available
Yes
Current price
$116.64
+2.62 (+2.30%)
Trailing / Forward P/E
37.75x
Forward: 19.23x
Market cap / Volume
Volume:
Revenue / Earnings Growth
13.0%
Earnings: -47.5%
Margins
14.7% op
Gross: 56.8% · Net: 11.6%
Balance sheet
1.38x current
Debt / Equity: 63.2
52-week range / Beta
$81.97 - $137.49
Beta: 0.58
Analyst target
$120.20
Upside: 3.1%
Cash / shareholder return
3.57% FCF yield
Dividend yield: 2.17%

Company context

Industry: Medical Devices
Country: United States
Employees:
Price to book: 3.95x
Return on equity: 10.6%
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Price chart

Market context for ABT

Competitive view

ABT vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Abbott Laboratories latest YouTube video thumbnail YouTube
Abbott Laboratories
ABT
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
ABT
$201.83B
Abbott Laboratories
ISRG
$135.72B
Intuitive Surgical
JNJ
$651.25B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
ABT
37.8x
Abbott Laboratories
ISRG
43.5x
Intuitive Surgical
JNJ
31.4x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
ABT
19.2x
Abbott Laboratories
ISRG
31.4x
Intuitive Surgical
JNJ
22.0x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
ABT
13.0%
Abbott Laboratories
ISRG
18.5%
Intuitive Surgical
JNJ
6.6%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
ABT
-47.5%
Abbott Laboratories
ISRG
26.5%
Intuitive Surgical
JNJ
-0.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
ABT
14.7%
Abbott Laboratories
ISRG
33.6%
Intuitive Surgical
JNJ
29.2%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
ABT
56.8%
Abbott Laboratories
ISRG
66.7%
Intuitive Surgical
JNJ
68.1%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
ABT
11.6%
Abbott Laboratories
ISRG
28.4%
Intuitive Surgical
JNJ
21.5%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
ABT
10.6%
Abbott Laboratories
ISRG
17.4%
Intuitive Surgical
JNJ
25.7%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
ABT
3.6%
Abbott Laboratories
ISRG
1.9%
Intuitive Surgical
JNJ
2.6%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
ABT
63.21x
Abbott Laboratories
ISRG
Intuitive Surgical
JNJ
57.71x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
ABT
1.38x
Abbott Laboratories
ISRG
4.96x
Intuitive Surgical
JNJ
1.09x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
ABT
0.58
Abbott Laboratories
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
ABT
2.2%
Abbott Laboratories
ISRG
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
ABT
3.1%
Abbott Laboratories
ISRG
26.2%
Intuitive Surgical
JNJ
0.8%
Johnson & Johnson

Related research

Non-quarter videos featuring ABT

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-17

Abbott Beat, Raised — Still Down 27%. Buy? #ABT #stocks #investing #dividendstocks #healthcare

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for ABT

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
2026-07-17
Published youtube podcast complete
ABT Stock: Abbott Beat AND Raised — So Why Is It Still Down 27%? (Bargain or Value Trap?)
Quarterly earnings-analysis entry for Abbott Laboratories. Use the links on the right to open the video or podcast episode.
Q1 2026
Episode live
2026-04-18
Published youtube complete
ABT Stock: $11.2B Revenue — Q1 2026 Earnings Analysis
Quarterly earnings-analysis entry for Abbott Laboratories. Use the links on the right to open the video or podcast episode.
Deep Dive
Episode live
2026-04-18
Published podcast complete
Charged Alpha | Abbott Laboratories (ABT) | S&P 500 Deep Dive — Ep. 152
Quarterly earnings-analysis entry for Abbott Laboratories. Use the links on the right to open the video or podcast episode.
Q4 2025
Episode live
2026-04-13
Published youtube podcast complete
Charged Alpha | Abbott Laboratories (ABT) | Q4 2025 Earnings Deep Dive — Ep. 112
Quarterly earnings-analysis entry for Abbott Laboratories. Use the links on the right to open the video or podcast episode.